Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038651 | 0.88 | L3MBTL1 (0.47) | ESR1HCRTR2KEAP1NFE2L2HCRTR1 | |
| SCHEMBL1039256 | 0.81 | HCRTR2 (0.51) | HCRTR2KEAP1NFE2L2HSD11B1 | |
| SCHEMBL1040417 | 0.81 | HCRTR2 (0.55) | HCRTR2KEAP1NFE2L2LMNARORC | |
| SCHEMBL1075444 | 0.80 | HCRTR2 (0.56) | HCRTR2KEAP1NFE2L2TP53 | |
| SCHEMBL1040887 | 0.79 | HTT (0.48) | ESR1HCRTR2KEAP1NFE2L2TAS2R14 | |
| SCHEMBL1040787 | 0.77 | NPSR1 (0.46) | HCRTR2LMNARORCCA12CA9 | |
| SCHEMBL1038837 | 0.73 | HCRTR2 (0.68) | ESR1HCRTR2KEAP1NFE2L2HCRTR1 | |
| SCHEMBL1035761 | 0.71 | ESR1 (0.43) | ESR1KEAP1NFE2L2HSD11B1LMNA | |
| SCHEMBL1040894 | 0.71 | HCRTR2 (0.62) | ESR1HCRTR2KEAP1NFE2L2HCRTR1 | |
| SCHEMBL1077747 | 0.71 | HCRTR2 (0.83) | HCRTR2KEAP1NFE2L2LMNARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-19 | — | — | US | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | HCRTR2, HCRTR1, GIPR | ESR1 702/4885HCRTR2 1/4885KEAP1 1611/4885 |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | HCRTR2, HCRTR1, GIPR | ESR1 702/4885HCRTR2 1/4885KEAP1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.